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Hurler’s syndrome (the most severe form of mucopolysaccharidosis type I) causes pro-
gressive deterioration of the central nervous system and death in childhood. Allogeneic
bone marrow transplantation before the age of two years halts disease progression and
prolongs life, but many children lack a bone marrow donor. We investigated the feasi-
bility of using cord-blood transplants from unrelated donors and a myeloablative prepar-





Between December 1995 and October 2002, 20 consecutive children with Hurler’s syn-
drome received busulfan, cyclophosphamide, and antithymocyte globulin before re-
ceiving cord-blood transplants from unrelated donors. The children were subsequently

















 per kilogram of body weight) and were discordant for up to three of six HLA
markers. Neutrophil engraftment occurred a median of 24 days after transplantation.
Five patients had grade II or grade III acute graft-versus-host disease; none had exten-
sive chronic graft-versus-host disease. Seventeen of the 20 children were alive a median









-iduronidase activity (event-free survival rate, 85 percent). Transplanta-





Cord blood from unrelated donors appears to be an excellent source of stem cells for
transplantation in patients with Hurler’s syndrome. Sustained engraftment can be
achieved without total-body irradiation. Cord-blood transplantation favorably altered
the natural history of Hurler’s syndrome and thus may be important to consider in young
children with this form of the disease.
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cord-blood transplantation in hurler’s syndrome
 
1961
urler’s syndrome (the most se-
 
vere form of mucopolysaccharidosis
type I), an autosomal recessive metabolic









idase, results in the accumulation of heparan and





 Severe phenotypes, in which
symptoms begin by two years of age, are character-
ized by severe, progressive deterioration of the cen-
tral nervous system, cardiac disease, skeletal abnor-





 Bone marrow transplantation can
prevent the progression of selected heritable en-
zyme deficiencies and provides maximal benefit




 More than 200 pa-
tients with Hurler’s syndrome have undergone





 Donor stem cells deliver enzyme in-
side and outside the blood compartment, arresting





 Unfortunately, many children who






umbilical-cord blood from unrelated donors with
partial HLA mismatches can provide donor stem





 we used cord blood from unre-
lated donors as the source of hematopoietic stem





Between December 28, 1995, and October 16,
2002, 20 consecutive children with Hurler’s syn-
drome who were referred to Duke University Medi-
cal Center for transplantation and who lacked HLA-
matched, related bone marrow donors who were
not carriers of the disease received cord-blood trans-
plants from unrelated donors. The diagnosis of
Hurler’s syndrome was confirmed on the basis of














were enrolled in a phase 1 and 2 study of cord-blood
transplantation for the treatment of nonmalignant
diseases approved by the institutional review board
of Duke University. The parents of each patient pro-




Searches for cord-blood units from unrelated do-
nors were conducted with the use of intermediate-
resolution typing for HLA class I (A and B) and high-
resolution typing for HLA-DRB1. The unit of cord





 per kilogram of body weight) that
matched at least three of six HLA loci was selected.


















Cryopreserved units of cord blood were thawed and




 The total num-
bers of nucleated cells, clonal hematopoietic pro-
genitor cells, and CD34+ cells were counted; ABO
and Rh typing was performed; the viability of the
cells was assessed; and bacterial and fungal cultures




All patients were prepared for transplantation by re-
ceiving 16 doses of busulfan (20 to 40 mg per square
meter of body-surface area orally, with the dose
based on age) from days 9 through 6 before trans-
plantation; 4 doses of cyclophosphamide (50 mg
per kilogram of body weight given intravenously)
from days 5 through 2 before transplantation; and
3 doses of antithymocyte globulin (Pharmacia–
Upjohn; 30 mg per kilogram given intravenously
from days 3 through 1 before transplantation). The
pharmacokinetics of busulfan were assessed after
the first dose, and subsequent doses were adjusted
to maintain a steady-state concentration of 600 to




 One patient required an in-
crease in the dose, and 11 patients required a de-
crease. Patients received phenytoin for prophylaxis
against seizures during treatment; busulfan and
mesna were also given for prophylaxis against hem-
orrhagic cystitis during cyclophosphamide therapy.
Radiation therapy was not used as part of the con-
ditioning regimen.
 
prophylaxis against and treatment 
of graft-versus-host disease
 
All children received cyclosporine for nine months
and methylprednisolone for two to three months





 The severity of acute GVHD was scored





grade I acute GVHD were treated with topical
creams, a small escalation in the dose of systemic
methylprednisolone, or both. Patients with moder-
ate acute GVHD received four pulsed doses of meth-
ylprednisolone (500 mg per square meter given in-
h
methods
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travenously every 12 hours) before treatment was





All patients were kept in reverse isolation rooms






fungal infections was used. Empirical treatment
with broad-spectrum antibiotics was started with
the first episode of febrile neutropenia and contin-
ued through engraftment. Intravenous immune
globulin was administered weekly through day 100.
A continuous infusion of low-dose heparin was used
as prophylaxis against veno-occlusive disease. Pa-
tients received transfusions of leukocyte-depleted,
irradiated, packed red cells and platelets. Filgrastim
(Amgen; 10 µg per kilogram per day) was adminis-
tered daily from the day of transplantation (day 0)
through engraftment. Engraftment was defined by
an absolute neutrophil count of at least 500 donor




Patients were evaluated every 6 to 12 months by mul-
tiple pediatric subspecialists in developmental pe-
diatrics, ophthalmology, audiology, cardiology (to
obtain echocardiograms and provide follow-up),
pulmonology, and orthopedics (to obtain hip and
spine films and provide follow-up). The Cobb
method was used to quantify the degree of ky-
phoscoliosis. Hip films were evaluated for sublux-
ation, acetabular coverage, and dysplasia. The need
for orthopedic surgery was determined on the basis
of radiographic and clinical findings. Neurocogni-
tive function was evaluated by the Program for the
Study of Neurodevelopmental Function in Rare Dis-
orders (Center for Development and Learning, Uni-
versity of North Carolina, Chapel Hill). Patients less
than three years of age were assessed with the Bayley
Scales of Infant Development, the Clinical Adaptive
Test–Clinical Linguistic Auditory Milestone Scale in
Early Cognitive Assessment, and the Mullen Scales
of Early Learning. Patients three years of age or old-
er were assessed with the Mullen Scales of Early
Learning and the Differential Abilities Scales. Stan-
dard scores, T scores, and developmental quotients
were converted to age-equivalent scores to allow




The probability of event-free survival was calculated
according to the Kaplan–Meier method. The prob-
abilities of all other events were calculated on the
basis of their cumulative incidence, with engraft-





 Adverse events were defined as
death, autologous recovery, and graft failure. Each
patient’s developmental course was assessed with
the use of the hierarchical linear model, which de-
picts changes in cognitive function over time. This
type of model allows for missing data and irregular
evaluation times. The contribution to the estimate
of the slope and intercept is greater for patients with
more data points than for those with fewer data
points. Linear and quadratic polynomial terms are
included to allow for nonlinear changes. The cutoff
date for data analysis was September 1, 2003.
 
characteristics of the patients
 
From December 1995 through October 2002, 20
children (10 boys and 10 girls) received cord-blood
transplants from unrelated donors. The median
weight of the children was 12 kg (range, 5 to 15).
The median age was 11 months (range, prenatal
to 29 months) at diagnosis and 16 months (range,
2 to 33) at transplantation (Table 1). Five patients
required ventriculoperitoneal shunts before trans-
plantation, but none required them after transplan-
tation.
 
selection of units for transplantation
 
Units of umbilical-cord blood were matched to the
patient’s HLA phenotype at three to six loci (Table 1).
Ten patients received units with major ABO-blood-
group incompatibilities. The mean number of nu-
cleated cells in units selected for transplantation














































Neutrophil and platelet engraftment occurred a me-
dian of 24 days (range, 10 to 39) and 56 days (range,
28 to 216), respectively, after transplantation (Table
2 and Fig. 1A and 1B). Red-cell and platelet trans-
fusions were no longer required after a median in-
terval of 48 days (range, 20 to 67) and 55 days
(range, 20 to 113), respectively, with patients requir-
ing a median of 10 transfusions of packed red cells
results
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and 28 platelet transfusions in the interim. As of the
last follow-up evaluation, all 17 surviving patients














Cellular and humoral immune function was as-
sessed quarterly for the first year after transplanta-
tion and yearly thereafter. CD4+ cell counts exceed-
ed 100 per cubic millimeter at three months, 200 per
cubic millimeter at six months, and 400 per cubic
millimeter at nine months. The degree of prolifera-
tion in response to phytohemagglutinin and the
absolute lymphocyte count were normal by nine
months after transplantation. All children were im-
munized with age-appropriate killed- and live-virus





The overall probability of moderate-to-severe acute
GVHD was 25 percent a median of 11 days (range,
8 to 35) after transplantation (Table 2). Limited,
chronic GVHD of the skin developed in two pa-










-Iduronidase activity was measured in peripheral-blood leukocytes. The normal range is 30 to 70 nmol per hour per milligram of protein.
 
† The patient had family members with Hurler’s syndrome and received a diagnosis prenatally.
 















































1 21 28 0.33 3/6 A29/34, 
DR1601/1602, 
DR1402/0701
4.88 3.10 6.51 12.4
2 21 31 0.46 5/6 B8/35 3.38 1.91 0.57 11.46
3 5 7 0.06 4/6 Abl/31, B62/bl 20.95 20.90 46.09 104.75
4 4 6 0.0 4/6 A24/26, DR1102/bl 5.78 4.66 1.40 13.98
5† 0 3 0.69 5/6 A28/29 18.63 15.70 51.81 8.01
6 8 16 0.0 5/6 B35/14 11.23 8.01 8.01 1.30
7 9 13 0.0 4/6 B8/35, B55/51 7.00 4.42 4.42 0.66
8 9 26 0.0 4/6 A31/23, B60/49 17.45 13.00 5.20 0.90
9 11 16 0.0 5/6 A3/24 8.69 8.67 15.61 3.99
10 11 14 0.4 5/6 A3/2 7.15 6.70 7.37 1.53
11 7 11 0.11 5/6 A33/24 5.03 5.08 2.54 0.91
12 12 15 0.0 5/6 B44/18 23.56 15.31 17.61 5.21
13 11 25 0.16 5/6 B51/7 8.46 6.02 16.56 5.60
14 20 22 0.0 4/6 A68/11, B37/1501 10.27 9.88 31.12 13.14
15 12 16 0.1 4/6 B27/14, DR0401/0301 12.73 11.68 1.17 1.71
16 16 17 0.0 6/6 7.97 5.84 2.04 1.80
17 26 31 1.1 5/6 B49/52 10.94 6.84 2.05 1.92
18 17 21 0.0 5/6 A11/31 9.01 6.07 6.68 1.54
19 29 33 0.25 3/6 Abl/2, Bbl/60, 
DRb1/1802
5.13 4.55 9.33 1.73
20† 0 2 0.25 5/6 A68/2 12.34 8.42 8.00 1.94
Mean ±SD 12±8 18±9 10.53±4.8 8.34±4.8 12.20±14.6 9.79±22.8
Median 11 16 8.85 6.77 7.02 2.51
The New England Journal of Medicine 
Downloaded from nejm.org on September 24, 2013. For personal use only. No other uses without permission. 
 Copyright © 2004 Massachusetts Medical Society. All rights reserved. 
 
























As of September 1, 2003, a median of 905 days af-
ter transplantation (range, 333 to 2817), 17 of 20
patients were alive, for an overall event-free survival
rate of 85 percent (Table 2 and Fig. 1C). One child
died of idiopathic hyperammonemia on day 32 after
transplantation, one of central nervous system hem-
orrhage related to cytomegalovirus infection on day
90, and one, who received two cord-blood trans-
plants, died of cytomegalovirus pneumonia 210
days after the first transplantation. Five children had
serious adverse effects from which they recovered:
hemolytic anemia in one, pulmonary hemorrhage
in one, gallbladder hydrops in one, and ventriculo-
peritoneal-shunt infection in two. The median hos-

















 were found in all 20 children before
transplantation, which is consistent with the pheno-
type of Hurler’s syndrome. Although some common
mutations have now been identified that are consis-
tently associated with the phenotype, many children
with severe disease have other rare or unidentified
 
* Myeloid engraftment was defined by an absolute neutrophil count of at least 500 per cubic millimeter on three consecutive days, and platelet 
engraftment was defined by a platelet count of at least 50,000 per cubic millimeter without the need for transfusion for at least seven consec-
utive days. Chimerism was evaluated by fluorescence in situ hybridization for XY if the donor and the patient were different sexes. Otherwise, 









-Iduronidase activity was measured in peripheral-blood leukocytes; the normal range is 30 to 70 nmol per hour per milligram of protein.
‡ The analysis of survival ended September 1, 2003.
 
§ The value was obtained at six months.
 




























1 34 82 100 100 31.4 I Skin 9 0 2817
2 39 NE II GI tract 18 NE Died on day 90
3 12 28 100 100 89.3 I Skin 20 0 2410
4 25 61 100 100 69.6 I Skin 7 0 2220
5 10 33 100 100 61.4 0 0 1815
6 18 81 100 100 48.5 0 0 1747
7 NE Died on day 32
8 30 74 100 100 74.4 I Skin 8 0 1487
9 24 90 100 100 105.8 I Skin 35 0 1481
10 23 66 100 100 51.9 0 0 1248
11 24 65 100 100 59.3 I Skin 17 0 905
12 21 67 >99 >99 60.0 III Skin, GI tract 8 0 814
13 21 71 100 100 57.8 I Skin 9 0 809
14 15 44 >99 >99 94.9 I Skin 28 0 751
15 30 216 >99 >99 51.1 II Skin 8 0 674
16 30 66 >99 >99 59.6 I Skin 13 0 542
17 28 88 100 100 39.3 II Skin 11 Limited (skin) 541
18 26 61 >99 >99 41.7 III Skin, GI tract 11 Limited (skin) 480
19 NE 44.6 Died on day 218
20 19 47 >99 >99§ 62.9 I Skin 9 0 333
Mean ±SD 24±7 71±32 >99 >99 I±I 14±8 0 1239±747
Median 24 56 >99 >99 I 11 0 905
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mutations. Two children in our series have been
identified as homozygotes and seven as compound
heterozygotes for common mutations associated
with the severe phenotype. Two previously unreport-





All children were evaluated serially to document the
late effects of cord-blood transplantation on Hurl-
er’s syndrome. Longitudinal growth was closely
monitored, and within one year after transplanta-
tion, growth velocity was normal in the majority of
patients and remained so (Fig. 2). Four of the chil-
dren have required spinal fusion for kyphosis, six
have had a spontaneous decrease in the degree of
kyphosis after transplantation, kyphosis has not
developed in two, and five have stable, mild kypho-
sis. One child has required hip surgery, and none
have undergone carpal-tunnel or knee surgery to
date. No child has had clinically significant cardiac
dysfunction. All children had either stable or im-
proved neurocognitive function after transplanta-
tion (Fig. 3A). Although the children quickly fell
behind in development in the immediate post-trans-
plantation period (slope=0.56 at 24 months), by 54
months of age the developmental slope had in-
creased to 0.81, and by 72 months they appeared to
be gaining cognitive skills at a slightly slower rate
(slope=0.95) than the mean for unaffected chil-
dren (Fig. 3B).
We describe the outcome in 20 children with Hurl-
er’s syndrome who received cord-blood transplants
from unrelated donors after the administration of a
chemotherapy-based preparative regimen. Eighty-
five percent of the children survived with complete








-iduronidase activity. In contrast, after bone
marrow transplantation, graft failure has been re-
ported in 28 to 37 percent of such patients, despite


















The limited availability of donors is a major ob-
stacle to bone marrow transplantation, with no suit-
able adult stem-cell donor identified in a timely
fashion in more than 50 percent of patients. Banked
umbilical-cord blood is prospectively HLA typed,
screened for infections and other risk factors, and
discussion
 
Figure 1. Cumulative Incidence of Neutrophil (Panel A) and Platelet (Panel B) Engraftment after Cord-Blood Transplantation 
and Kaplan–Meier Estimates of the Probability of Event-free Survival (Panel C).
 
In Panel A, myeloid engraftment was defined by an absolute neutrophil count of at least 500 per cubic millimeter on three consecutive days. 
The one patient who remained aplastic after the first cord-blood transplantation received a second cord-blood transplant on day 63. Myeloid 
engraftment occurred on day 26 after the second transplantation. In Panel B, platelet engraftment was defined by a platelet count of at least 
50,000 per cubic millimeter without the need for transfusion for at least seven consecutive days. In Panel C, event-free survival was defined by 
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readily available for transplantation. In our study,
the average time from the initiation of a search for a
donor to the identification of a compatible unit of









ronidase activity) was 15 days. The time from the ini-
tiation of a search to the beginning of the condition-
ing regimen for transplantation was 41 days (31
days among patients who underwent transplanta-
tion after 2000). In a disease in which the time from
diagnosis to definitive treatment may represent a
crucial period in which to prevent further disease
progression, a readily available source of stem cells
is extremely desirable. 
An additional advantage of the use of umbilical
cord blood is that HLA matching does not have to be
as close as that necessary for bone marrow grafts;
this allows a donor to be identified for virtually all
patients. Despite mismatching at one to three HLA
loci in most donor–recipient pairs in our series, en-
graftment and immune reconstitution were com-
plete, and the rates of acute and chronic GVHD were
low. No deaths were attributable to GVHD, and none
of the children had extensive chronic GVHD. By con-
trast, among children with Hurler’s syndrome who
receive bone marrow transplants from unrelated do-
nors, the rates of GVHD have been reported to be





Hematopoietic stem-cell transplantation arrests
the progression of Hurler’s syndrome, averting
death from cardiac causes and liver disease, improv-





 Untreated children with Hurler’s syn-
drome have severe growth failure by the age of two





ter cord-blood transplantation, the children in our
study had normal growth velocities. Hurler’s syn-
drome is associated with skeletal abnormalities,
including kyphosis, hip dysplasia, and carpal tun-
nel syndrome, which cause serious complications





data regarding the effect of hematopoietic stem-cell
 
Figure 2. Growth of Boys (Panel A) and Girls (Panel B) from the Age of Two Years until the Last Follow-up Visit.
 
Most of the children had normal growth velocity within one year after transplantation. The gray curves represent stan-
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 Some clear benefits have been





 In our series, five children required ortho-
pedic intervention, whereas the remainder have had
stabilization or regression of bony disease after
transplantation, obviating the need for surgical in-
tervention. Since the median age of these children
is currently 4.5 years (range, 11 months to 10 years),
additional long-term follow-up is needed to deter-
mine the full effect of cord-blood transplantation on
the progression of the skeletal manifestations of
Hurler’s syndrome.
Fifteen of the 17 surviving children were serially
evaluated by the neurodevelopmental team before
and after transplantation. After the initial post-
transplantation period of developmental delay, neu-
rocognitive function stabilized or improved in all the
children, and all have continued to gain skills. Three
of the four oldest children have average-to-high IQs,
although their genotypes and the results of protein
analysis would predict them to have severe disease
with rapid neurocognitive decline. Although results
at 54 months were available for only four patients
(24 percent of the group) and are therefore incon-
clusive, there was a trend toward increasing cogni-
tive skills, with the mean scores of the sample fall-
ing within the normal range by 66 months of age.








-iduronidase has ameliorated some manifesta-
tions of disease in patients older than six years who




Such patients form nonneutralizing antibodies that
do not appear to interfere with the efficacy of treat-
ment.33 Enzyme-replacement therapy is now being
tested in limited numbers of more severely affected
infants and younger children. Since the enzyme is
unlikely to be able to cross the blood–brain barrier,
transplantation therapy will continue to be used in
children with Hurler’s syndrome. Because of possi-
ble clinical gains with earlier exposure to enzyme, it
is tempting to consider instituting enzyme-replace-
ment therapy in patients with Hurler’s syndrome
while they are being prepared for transplantation.
However, it is difficult to predict the nature of the
antibody response and its possible influence on the
efficacy of transplantation. Therefore, the pretrans-
plantation use of enzyme-replacement therapy in
the most severely affected patients with Hurler’s
syndrome should be tested in a controlled clinical
trial and used with caution.
The children in this series underwent cord-blood
Figure 3. Neurocognitive Performance of Children with Hurler’s Syndrome 
after Cord-Blood Transplantation (Panel A) and as Compared with That 
of Unaffected Children (Panel B).
We used age-equivalent scores for comparisons and to monitor the children’s 
developmental progress. Panel A shows the cognitive trajectories achieved by 
plotting developmental age against chronologic age for each child over time. 
A slope of 1.0 (the straight red line) indicates normal developmental velocity. 
Panel B shows the mean cognitive growth curve for all surviving patients plot-
ted against the mean typical cognitive growth curve for unaffected children. 
The two thin black lines indicate the 95 percent confidence interval for the pa-
tients. The shaded area indicates the variability (±2 SD) in typical cognitive 
development. Only two of the patients (three observations) had data record-
ed before six months of age, and these observations were not included in the 
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transplantation at a median age of 16 months. In
previous studies of bone marrow transplantation in
patients with Hurler’s syndrome, the median age
was older — 19 to 24 months.9,11,13,14 Children
who undergo transplantation at a younger age may
derive more benefit, regardless of the source of the
stem cells. Additional studies are needed to deter-
mine whether the positive outcomes in this study
are related to the stem-cell source, the age at trans-
plantation, or both.
In summary, we found that hematopoietic stem-
cell transplantation with banked cord blood from
partially HLA-matched, unrelated donors favorably
altered the natural history of Hurler’s syndrome. En-
graftment and full donor chimerism were achieved
and maintained without the use of radiation therapy.
The incidence of acute GVHD was low, and exten-
sive chronic GVHD did not occur. Donors were
readily and rapidly available. The overall event-free
survival rate was 85 percent after a median follow-up
of more than two years. Although long-term follow-
up is needed to determine the full effect of cord-
blood transplantation on the natural history of Hurl-
er’s syndrome, patients appear to derive important
benefits from this therapy. It may prove to be a ther-
apeutic option for young patients with Hurler’s syn-
drome who lack an HLA-matched, related bone
marrow donor who is not a carrier of the disease.
Supported in part by the National Heart, Lung, and Blood Insti-
tute of the National Institutes of Health through the enrollment of
patients in the Cord Blood Transplantation Study.
We are indebted to the inpatient and outpatient nursing staffs,
physicians, and nurse practitioners of the Pediatric Stem Cell Trans-
plant Program at Duke University Medical Center for caring for the
patients; to the staff of the pediatric stem-cell laboratory for pro-
cessing the units of umbilical-cord blood; to Dr. Robert Fitch of Pe-
diatric Orthopedics at Duke University Medical Center for providing
orthopedic care; and to the referring physicians and parents of the
children for allowing us to treat them and study the consequences of
umbilical-cord blood transplantation.
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